0 items USD 0.00Top 10 Antidiabetics Pharma Companies in the World
Global antidiabetics market is expected to be worth USD 56.18 billion by 2023 as per newly launched report by NAVADHI Market Research.
Based on the antidiabetic revenue the top 10 antidiabetics pharmaceutical companies in the world are:
- Novo Nordisk A/S : USD 14.26 billion
- Eli Lilly and Company : USD 9.71 billion
- Sanofi S.A. : USD 6.10 billion
- Merck & Co. Inc : USD 5.91 billion
- Boehringer Ingelheim : USD 3.37 billion
- AstraZeneca PLC : USD 2.60 billion
- Johnson & Johnson : USD 0.88 billion
- Merck KGaA : USD 0.86 billion
- Bayer : USD 0.62 billion
- Takeda Pharmaceutical Company Limited : USD 0.42 billion
Global Antidiabetics Pharmaceutical Market Forecast 2023
Global antidiabetics pharmaceutical market is expected to be worth USD 56.18 billion by 2023.
1 . 1. Novo Nordisk A/S
Novo Nordisk is a global healthcare company with 95 years of innovation and one of the leading companies in diabetes care. It is headquartered in Denmark and has three business segments: diabetes, obesity and biopharmaceuticals.
Novo Nordisk is world's largest antidiabetics pharmaceutical company. In FY 2018 the company's diabetes pharma revenue was USD 14.26 billion. Some of the key antidiabetic products of Novo Nordisk with more than USD 1 billion revenue in FY 2018 were NovoMix/NovoLog Mix, NovoRapid/NovoLog, Victoza, Tresiba and Levemir. Novo Nordisk also manufactures obesity treatment drug Saxenda which had a revenue of USD 0.613 billion in FY 2018.
2 . 2. Eli Lilly and Company
Eli Lilly and Company was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly.
Eli Lilly is world's second largest antidiabetics pharmaceutical company. In FY 2018 the company's diabetes pharma revenue was USD 9.71 billion. Some of the key antidiabetic products of Eli Lilly with more than USD 1 billion revenue in FY 2018 were Humalog, Humulin and Trulicity.
3 . 3. Sanofi S.A.
Sanofi S.A. is a Paris based, French multinational pharmaceutical company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions.
Sanofi is world's third largest antidiabetics pharmaceutical company. In FY 2018 the company's diabetes pharma revenue was USD 6.10 billion. Some of the key antidiabetic products of Sanofi with highest revenue in FY 2018 were Lantus, Toujeo, Apidra and Amaryl.
4 . 4. Merck & Co. Inc
Merck & Co., Inc. was founded in 1891 and delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.
Merck & Co. is world's fourth largest antidiabetics pharmaceutical company. In FY 2018 the company's diabetes pharma revenue was USD 5.91 billion. Some of the key antidiabetic products of Merck & Co. with more than USD 1 billion revenue in FY 2018 were Januvia and Janumet.
5 . 5. Boehringer Ingelheim
C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim GmbH, which was founded in 1885 by Albert Boehringer in Ingelhim am Rhein Germany. It has two business segments: human pharmaceuticals and animal health.
Boehringer Ingelheim is world's fifth largest antidiabetics pharmaceutical company. In FY 2018 the company's diabetes pharma revenue was USD 3.37 billion. Some of the key antidiabetic products of Boehringer Ingelheim with more than USD 1 billion revenue in FY 2018 were Jardiance and Trajenta.
6 . 6. AstraZeneca PLC
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory.
AstraZeneca is world's sixth largest antidiabetics pharmaceutical company. In FY 2018 the company's diabetes pharma revenue was USD 2.60 billion. Some of the key antidiabetic products of AstraZeneca with highest revenue in FY 2018 were Farxiga, Onglyza and Bydureon.
7 . 7. Johnson & Johnson
Johnson & Johnson was incorporated in the State of New Jersey in 1887. It is organized into three business segments: Consumer, Pharmaceutical and Medical Devices.
Johnson & Johnson is world's seventh largest antidiabetics pharmaceutical company. In FY 2018 the company's diabetes pharma revenue was USD 0.88 billion. Johnson & Johnson’s highest revenue earner antidiabetic product in FY 2018 was Invokana/ Invokamet.
8 . 8. Merck KGaA
The Merck Group, branded and commonly known as Merck, is a German multinational pharmaceutical, chemical and Life Sciences Company headquartered in Darmstadt. Its main product divisions are oncology, neurology & immunology, fertility and general medicine & endocrinology.
Merck KGaA is world's eighth largest antidiabetics pharmaceutical company. In FY 2018 the company's diabetes pharma revenue was USD 0.86 billion. Merck KGaA’s highest revenue earner antidiabetic product in FY 2018 was Glucophage.
9 . 9. Bayer
Bayer is a German multinational pharmaceutical and life sciences company with a more than 150-year history and core competencies in the areas of health care and agriculture, is one of the largest pharmaceutical companies in the world.
Bayer is world's ninth largest antidiabetics pharmaceutical company. In FY 2018 the company's diabetes pharma revenue was USD 0.62 billion. Bayer’s highest revenue earner antidiabetic product in FY 2018 was Glucobay.
10 . 10. Takeda Pharmaceutical Company Limited
Takeda is Tokyo headquartered company which was established in 1781. Takeda focuses on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Disease. They also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. On 8th January, 2019 Takeda acquired Shire Plc at USD 62 billion which is expected to boost it’s overall revenue in FY 2019 by 57.35%.
Takeda is world's tenth largest antidiabetics pharmaceutical company. In FY 2018 the company's diabetes pharma revenue was USD 0.49 billion. Takeda’s highest revenue earner antidiabetic product in FY 2018 was Nesina.
Global antidiabetics pharmaceutical market is expected to be worth USD 56.18 billion by 2023.
Related Pharmaceutical Industry Articles
1. Global Pharmaceuticals Market Forecast: Drivers, Value Chain Analysis & Trends
2. Top 15 Pharma Companies in India
3. U.S. Top 10 Pharmaceutical Companies by Market Turnover
4. World's Top Selling Pharmaceutical Drugs and Manufacturers by Sales
5. Top 6 Therapeutic Companies to Look out for Acute Renal Failure (Acute Kidney Injury)
6. Top 10 Oncology Pharma Companies in the World
7. Top 10 Asthma Drugs in the World
Email a colleague
Printer version
Send by email
About The Author
Latest Antidiabetic Pipeline Reports
Diabetic Macular Edema - Pipeline Review, H1 2019
Diabetic Peripheral Neuropathy - Pipeline Review, H1 2019
Diabetic Foot Ulcers - Pipeline Review, H2 2018
Diabetic Gastroparesis - Pipeline Review, H1 2019
Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease
Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018
Diabetes Assays - Medical Devices Pipeline Assessment, 2018
